Substance / Medication

Telotristat

Overview

Active Ingredient
telotristat
RxNorm CUI
1872382

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Management of carcinoid syndrome: a systematic review and meta-analysis.
Hofland Johannes, Herrera-Martínez Aura D, Zandee Wouter T et al. · Endocr Relat Cancer · 2019
PMID: 30608900Meta-Analysis
Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review.
Seymour Nicole, Sawh Sonja C · Can J Anaesth · 2013
PMID: 23328959Meta-Analysis
Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome.
Dillon Joseph S, Kulke Matthew H, Hörsch Dieter et al. · J Gastrointest Cancer · 2021
PMID: 32146619TrialFull text (PMC)
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
Pavel Marianne, Gross David J, Benavent Marta et al. · Endocr Relat Cancer · 2018
PMID: 29330194TrialFull text (PMC)
Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.
Weickert Martin O, Kaltsas Gregory, Hörsch Dieter et al. · Clin Ther · 2018
PMID: 29724499Trial
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
Kulke Matthew H, Hörsch Dieter, Caplin Martyn E et al. · J Clin Oncol · 2017
PMID: 27918724Trial
Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial.
Pavel Marianne, Hörsch Dieter, Caplin Martyn et al. · J Clin Endocrinol Metab · 2015
PMID: 25636046Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Telotristat (substance)
SNOMED CT
733734004
UMLS CUI
C3884837
RxNorm CUI
1872382

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Telotristat: Uses, Evidence & Side Effects | Ltrl